US Government Rejects Attempts to Lower Price of Cancer Drug Xtandi.

The National Institutes of Health has declined to use "march-in" rights to lower the price of Astellas and Pfizer's prostate cancer drug Xtandi despite being invented at UCLA with grants from the US Army and NIH. The institutes' analyses found Xtandi "to be widely available to the public," an indication that there was not a pressing need for the US to act. Under the Bayh-Dole Act, the government can promote the commercialization and public availability of even partially government-funded inventions, but the move has never been successful.